All In Biotech

Drug Trial Radar · NCT02514577

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Jan 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 217 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

217

Actual

Start

Nov 7, 2015

Primary completion

May 1, 2017

Study completion May 1, 2017

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Aug 3, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Conditions

  • Plaque Psoriasis

Interventions

  • IDP-122 LotionDrug

    Topical lotion

  • IDP-122 Vehicle LotionDrug

    Topical lotion. No active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Success at Week 8Time frame: Week 8

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Valeant Site 11

    Hot Springs, Arkansas

  • Valeant Site 1

    Encinitas, California

  • Valeant Site 10

    Encino, California

  • Valeant Site 12

    Santa Rosa, California

  • Valeant Site 13

    Atlanta, Georgia

  • Valeant Site 7

    Boise, Idaho

  • Valeant Site 6

    Rockville, Maryland

  • Valeant Site 4

    Ann Arbor, Michigan

  • Valeant Site 8

    Clarkston, Michigan

  • Valeant Site 15

    Las Vegas, Nevada

  • Valeant Site 9

    Raleigh, North Carolina

  • Valeant Site 5

    Knoxville, Tennessee

  • Valeant Site 3

    Austin, Texas

  • Valeant Site 2

    San Antonio, Texas

  • Valeant Site 14

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.